The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM D

FORM D

OMB APPROVAL			
OMB Number:	3235-0076		
Estimated average burd	en		
hours per response:	4.00		

Notice of Exempt Offering of Securities

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Names	X None	Entity Type
0001442836			X Corporation
Name of Issuer			Limited Partnership
MERSANA THERAPEUTICS IN	NC		Limited Liability Company
Jurisdiction of Incorporation/O	rganization		
DELAWARE			General Partnership
Year of Incorporation/Organiza	ation		Business Trust
X Over Five Years Ago			Other (Specify)
Within Last Five Years (Sp	pecify Year)		
Yet to Be Formed	,		
Tot to be I dillied			
2. Principal Place of Busines	ss and Contact Information		
Name of Issuer			
MERSANA THERAPEUTICS IN	IC		
Street Address 1		Street Address 2	
840 MEMORIAL DRIVE			
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
CAMBRIDGE	MA	02139	617-498-0020
3. Related Persons			
Last Name	First Name		Middle Name
Olson	Julie		A.
Street Address 1	Street Address 2		
840 Memorial Drive			
City	State/Province/Co	ountry	ZIP/PostalCode
Cambridge	MA		02139
Relationship: $\overline{\mathbf{X}}$ Executive Of	ficer X Director Promoter		
Clarification of Response (if Ne	ecessary):		
Last Name	First Name		Middle Name
Leone	Peter		
Street Address 1	Street Address 2		
840 Memorial Drive			
City	State/Province/Co	ountry	ZIP/PostalCode
Cambridge	MA	•	02139
Relationship: X Executive Of	ficer Director Promoter		
—Clarification of Response (if Ne	ecessary):		
Last Name	First Name		Middle Name
Bacopoulous	Nicholas		G.
Street Address 1	Street Address 2		
840 Memorial Drive			

City	State/Province/Country	ZIP/PostalCode	
Cambridge	MA	02139	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessa	ry):		
Last Name	First Name	Middle Name	
Boyd	C.	Clarke	
Street Address 1	Street Address 2		
840 Memorial Drive			
City	State/Province/Country	ZIP/PostalCode	
Cambridge	MA	02139	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessa	ry):		
Last Name	First Name	Middle Name	
Tsang	Joyce		
Street Address 1	Street Address 2		
840 Memorial Drive			
City	State/Province/Country	ZIP/PostalCode	
Cambridge	MA	02139	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessa	ry):		
Last Name	First Name	Middle Name	
Vogelbaum	Martin		
Street Address 1	Street Address 2		
840 Memorial Drive			
City	State/Province/Country	ZIP/PostalCode	
Cambridge	MA	02139	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessa	ry):		
Last Name	First Name	Middle Name	
Beck	Thomas		
Street Address 1	Street Address 2		
840 Memorial Drive			
City	State/Province/Country	ZIP/PostalCode	
Cambridge	MA	02139	
Relationship: Executive Officer	Director Promoter		
Clarification of Response (if Necessa	ry):		

4. Industry Group

Agriculture	Health Care Retailing
Banking & Financial Services	X Biotechnology Restaurants
Commercial Banking	Health Insurance Technology
Insurance	Hospitals & Physicians Computers
Investing	
Investment Banking	
Pooled Investment Fund	Other Health Care Other Technology
Is the issuer registered as an investment company under	Manufacturing Travel
the Investment Company	Real Estate Airports
Act of 1940?	Commercial Lodging & Conventions
YesNo	Construction Tourism & Travel Services
Other Banking & Financial Services	REITS & Finance Other Travel
Business Services	Residential
Energy	Other Real Estate
Coal Mining	
Electric Utilities	
Energy Conservation	
Environmental Services	
Oil & Gas	
☐ Other Energy	
5. Issuer Size	
J. 155UEI 312E	
	Aggregate Net Asset Value Range
Revenue Range OR No Revenues	Aggregate Net Asset Value Range No Aggregate Net Asset Value
Revenue Range OR	
Revenue Range OR No Revenues	No Aggregate Net Asset Value
Revenue Range OR No Revenues \$1 - \$1,000,000	No Aggregate Net Asset Value \$1 - \$5,000,000
Revenue Range OR No Revenues \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 -	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000
Revenue Range OR No Revenues \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000
Revenue Range OR No Revenues \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000
Revenue Range OR No Revenues \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose
Revenue Range OR No Revenues \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable
Revenue Range OR No Revenues \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable
Revenue Range OR No Revenues \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable
Revenue Range OR No Revenues	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply)
Revenue Range OR No Revenues	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Rule 505
Revenue Range OR No Revenues \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Clair Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i)	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Rule 505 X Rule 506
Revenue Range OR No Revenues	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable Not Applicable Net Select all that apply) Rule 505 X Rule 506 Securities Act Section 4(5)
Revenue Range OR No Revenues	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable Not Applicable Rule 505 X Rule 506 Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(9)
Revenue Range OR No Revenues	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable Securities Act Section 4(5) Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(9) Section 3(c)(2) Section 3(c)(10)
Revenue Range OR No Revenues	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable Not Applicable Net Applicable Not Applicable Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(1) Section 3(c)(10) Section 3(c)(3) Section 3(c)(11)
Revenue Range OR No Revenues	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable Not Applicable Not Applicable Not Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(10) Section 3(c)(3) Section 3(c)(11) Section 3(c)(11) Section 3(c)(11) Section 3(c)(11) Section 3(c)(12)
Revenue Range OR No Revenues	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable Not Applicable Net Applicable Not Applicable Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(1) Section 3(c)(10) Section 3(c)(3) Section 3(c)(11)
Revenue Range OR No Revenues	No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable Not Applicable Not Applicable Not Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(10) Section 3(c)(3) Section 3(c)(11) Section 3(c)(11) Section 3(c)(11) Section 3(c)(11) Section 3(c)(12)

7. Type of Filing		
X New Notice Date of First Sale 2010-01-19 First Sale Yet t	to Occur	
Amendment		
8. Duration of Offering		
Does the Issuer intend this offering to last more than one year?	Yes X No	
9. Type(s) of Securities Offered (select all that apply)		
Equity	Pooled Investment Fund Interests	
X Debt	Tenant-in-Common Securities	
Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities	
Security to be Acquired Upon Exercise of Option, Warrant or C Right to Acquire Security	Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combina merger, acquisition or exchange offer?	ation transaction, such as a Yes X No	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$0 USD		
12. Sales Compensation		
Recipient	Recipient CRD Number X None	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number $\overline{\mathbf{X}}$ None	
Street Address 1	Street Address 2	710/0 / 10 /
State(s) of Solicitation (select all that apply)	State/Province/Country	ZIP/Postal Code
Check "All States" or check individual States All States	Foreign/non-US	
13. Offering and Sales Amounts		
Total Offering Amount \$3,500,000 USD or Indefinite		
Total Amount Sold \$2,500,000 USD		
Total Remaining to be Sold \$1,000,000 USD or Indefinite		
Clarification of Response (if Necessary):		
14. Investors		
Select if securities in the offering have been or may be sold to enter the number of such non-accredited investors who alread		
Regardless of whether securities in the offering have been or investors, enter the total number of investors who already have		7
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finders estimate and check the box next to the amount.	fees expenses, if any. If the amount of an expenditure is no	ot known, provide an
Sales Commissions \$0 USD Estimate		
Finders' Fees \$0 USD Estimate		
Clarification of Response (if Necessary):		
16. Use of Proceeds		

Provide the amount of the gross	proceeds of the offering	g that has been or is propo	osed to be used for payment	s to any of the person	s required to
be named as executive officers,	directors or promoters	in response to Item 3 above	ve. If the amount is unknown	n, provide an estimate	and check the
box next to the amount.					

\$0 USD Estimate	
Clarification of Response (if Necessary):	
Signature and Submission	

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
MERSANA THERAPEUTICS INC	/s/ Julie A. Olson	Julie A. Olson	President & CEO	2010-02-25

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.